[go: up one dir, main page]

RU2014154366A - APPLICATION OF THE PROBIOTIC STRAIN OF THE MICROOORGANISM ENTEROCOCCUS FAECIUM L3 FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - Google Patents

APPLICATION OF THE PROBIOTIC STRAIN OF THE MICROOORGANISM ENTEROCOCCUS FAECIUM L3 FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Download PDF

Info

Publication number
RU2014154366A
RU2014154366A RU2014154366A RU2014154366A RU2014154366A RU 2014154366 A RU2014154366 A RU 2014154366A RU 2014154366 A RU2014154366 A RU 2014154366A RU 2014154366 A RU2014154366 A RU 2014154366A RU 2014154366 A RU2014154366 A RU 2014154366A
Authority
RU
Russia
Prior art keywords
neurodegenerative diseases
enterococcus faecium
microoorganism
treatment
application
Prior art date
Application number
RU2014154366A
Other languages
Russian (ru)
Other versions
RU2642246C2 (en
Inventor
Ирина Николаевна Абдурасулова
Елена Анатольевна Тарасова
Елена Игоревна Ермоленко
Анна Викторовна Мацулевич
Александр Николаевич Суворов
Original Assignee
Федеральное государственное бюджетное учреждение "Научно-исследовательский институт экспериментальной медицины" Северо-западного отделения РАМН (ФГБУ "НИИЭМ" СЗО РАМН)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное бюджетное учреждение "Научно-исследовательский институт экспериментальной медицины" Северо-западного отделения РАМН (ФГБУ "НИИЭМ" СЗО РАМН) filed Critical Федеральное государственное бюджетное учреждение "Научно-исследовательский институт экспериментальной медицины" Северо-западного отделения РАМН (ФГБУ "НИИЭМ" СЗО РАМН)
Priority to RU2014154366A priority Critical patent/RU2642246C2/en
Publication of RU2014154366A publication Critical patent/RU2014154366A/en
Application granted granted Critical
Publication of RU2642246C2 publication Critical patent/RU2642246C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Способ лечения нейродегенеративных заболеваний путем перорального применения пробиотика, отличающийся тем, что в качестве такового применяется штамм Enterococcus faecium L-3.A method of treating neurodegenerative diseases by oral administration of a probiotic, characterized in that the Enterococcus faecium L-3 strain is used as such.

Claims (1)

Способ лечения нейродегенеративных заболеваний путем перорального применения пробиотика, отличающийся тем, что в качестве такового применяется штамм Enterococcus faecium L-3. A method of treating neurodegenerative diseases by oral administration of a probiotic, characterized in that the Enterococcus faecium L-3 strain is used as such.
RU2014154366A 2014-12-30 2014-12-30 Application of probiotic strain of enterococcus faecium l-3 microorganism for neurodegenerative diseases treatment RU2642246C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2014154366A RU2642246C2 (en) 2014-12-30 2014-12-30 Application of probiotic strain of enterococcus faecium l-3 microorganism for neurodegenerative diseases treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2014154366A RU2642246C2 (en) 2014-12-30 2014-12-30 Application of probiotic strain of enterococcus faecium l-3 microorganism for neurodegenerative diseases treatment

Publications (2)

Publication Number Publication Date
RU2014154366A true RU2014154366A (en) 2016-07-20
RU2642246C2 RU2642246C2 (en) 2018-01-24

Family

ID=56413362

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014154366A RU2642246C2 (en) 2014-12-30 2014-12-30 Application of probiotic strain of enterococcus faecium l-3 microorganism for neurodegenerative diseases treatment

Country Status (1)

Country Link
RU (1) RU2642246C2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018215759A1 (en) * 2017-05-22 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strains

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2734718C1 (en) * 2019-12-31 2020-10-22 Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") Method of reducing manifestation of non-motor symptoms in patients with parkinson's disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2610828A1 (en) * 2005-06-14 2006-12-28 Schering Corporation Heterocyclic aspartyl protease inhibitors, preparation and use thereof
RU2491097C1 (en) * 2012-02-16 2013-08-27 Общество с ограниченной ответственностью "НТфарма" Pharmaceutical composition and method of therapy of neurodegenerative disorders, including amyotrophic lateral sclerosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018215759A1 (en) * 2017-05-22 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strains

Also Published As

Publication number Publication date
RU2642246C2 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
MX2021006581A (en) Bacteria engineered to treat diseases associated with hyperammonemia.
EA201691582A1 (en) NEW PHARMACEUTICAL PREPARATIONS
MX2023008693A (en) Modulatory polynucleotides.
TW201613901A (en) New compounds
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
EA201691594A1 (en) CYCLOPROPYLAMINES AS LSD1 INHIBITORS
MY192927A (en) Fused bicyclic compounds for the treatment of disease
EA201691481A1 (en) C5a inhibitors for the treatment of viral pneumonia
CY1122264T1 (en) PPAR COMPOUNDS FOR USE IN THE TREATMENT OF FIBROTIC DISEASES
MX369623B (en) Fused bicyclic compounds for the treatment of disease.
BR112016019825A2 (en) complement factor bb antibodies
EA201791110A1 (en) SUBLINGUAL INTRODUCTION OF RHYNESOL
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
MX2021007899A (en) Selective il-6-trans-signalling inhibitor compositions.
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
UY36173A (en) METHOD OF TREATMENT OF DISEASES RELATED TO THE INDICATABLE FACTOR FOR HYPOXIA
MX2017012596A (en) A pharmaceutical composition and the use thereof.
MX2017014456A (en) Therapeutic uses of l-4-chlorokynurenine.
EA201791845A1 (en) SOLID FORMS OF MENAHINOLS
EA201692020A1 (en) PROTECTIVE MEANS OF AMERICA ACID FOR APPLICATION IN THE TREATMENT OF LACTOACIDOSIS OR INDIVIDUAL BY MEDICINAL MEANS OF THE DIFFERENT ACTION DUE TO THE COMPLEX I AND OXIDATIVE DISORDERS OF OXIDATIVE CHEMICAL REFERENCES AGREES
NZ730092A (en) Use of cysteamine in treating infections caused by yeasts/moulds
CL2016002321A1 (en) Compounds derived from 2-8-5-chloropyrimidin-2-ylamino-6,7,8,9-tetrahydro-5h-pyrido3,2-bindol-5-ylacetic acid, modulators of the prostaglandin d2 receptor pharmaceutical composition and its use for the treatment of diseases allergic immune disorders.
RU2014154366A (en) APPLICATION OF THE PROBIOTIC STRAIN OF THE MICROOORGANISM ENTEROCOCCUS FAECIUM L3 FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
BR112016015578A2 (en) 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 AND TYPE 2 INHIBITORS
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
MM4A The patent is invalid due to non-payment of fees

Effective date: 20181231